Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study.

Arschang ValipourSergey N AvdeevAdam BarczykValentina BayerZvi G FridlenderMariela GeorgievaOndřej KudelaAlexey MedvedchikovRamona MironMaria SanzharovskayaVirginija ŠileikienėJurij ŠorliMarc SpielmannsZsuzsanna Szalai

Published in: International journal of chronic obstructive pulmonary disease (2021)

In 4700 COPD patients, 6 weeks' treatment with tiotropium/olodaterol, as initial treatment or follow-up to LAMA or LABA monotherapy or LABA/ICS, improved CCQ and decreased rescue medication use. The adverse event profile was consistent with the known safety profile of tiotropium/olodaterol.

Keyphrases

clinical practice
chronic obstructive pulmonary disease
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
replacement therapy
air pollution
preterm birth
adverse drug